Abstract
Exposure to osimertinib (osi), a 3rd generation TKI for treatment of non-small cell lung cancer (NSCLC) and a sensitizing epidermal growth factor receptor (EGFR) mutation is variable between patients (pts). We evaluated the boosting capacity of cobicistat (cobi), a strong Cytochrome P450 3A (CYP3A)-inhibitor, on osi exposure in pts with NSCLC and low osi plasma trough concentration.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
